Related references
Note: Only part of the references are listed.A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer
Channing J. Paller et al.
PROSTATE (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer
Daniel P. Petrylak et al.
PROSTATE (2019)
Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer
Joan Caries et al.
CLINICAL GENITOURINARY CANCER (2018)
PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.
Michael J. Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The Epidemiology of Prostate Cancer
Claire H. Pernar et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
Yuki Kita et al.
CANCERS (2018)
Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database
Lindsay M. Burt et al.
ADVANCES IN RADIATION ONCOLOGY (2018)
The Diagnosis and Treatment of Prostate Cancer A Review
Mark S. Litwin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Clinical PET Imaging in Prostate Cancer
Kathryn L. Wallitt et al.
RADIOGRAPHICS (2017)
Navigating the evolving therapeutic landscape in advanced prostate cancer
E. David Crawford et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Phase 1 multicenter trial of brentuximab vedotin for steroid- refractory acute graft-versus-host disease
Yi-Bin Chen et al.
BLOOD (2017)
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Lesley J. Scott
DRUGS (2017)
Addition of PSMA ADC to Enzalutamide Therapy Significantly Improves Survival in In Vivo Model of Castration Resistant Prostate Cancer
Vincent A. DiPippo et al.
PROSTATE (2016)
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
J. F. Liu et al.
ANNALS OF ONCOLOGY (2016)
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
Heather Donaghy
MABS (2016)
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer
Matthew I. Milowsky et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Advances in the management of castration resistant prostate cancer
Chad R. Ritch et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Advances in the management of castration resistant prostate cancer
Chad R. Ritch et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
K. Chi et al.
ANNALS OF ONCOLOGY (2015)
Efficacy Studies of an Antibody-Drug Conjugate PSMA-ADC in Patient-Derived Prostate Cancer Xenografts
Vincent A. DiPippo et al.
PROSTATE (2015)
Synergistic Co-Targeting of Prostate-Specific Membrane Antigen and Androgen Receptor in Prostate Cancer
Jose D. Murga et al.
PROSTATE (2015)
Aggressive Variants of Castration-Resistant Prostate Cancer
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Michelle A. Fanale et al.
CLINICAL CANCER RESEARCH (2012)
GCPII Imaging and Cancer
C. A. Foss et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients withMetastaticBreast Colorectal and Prostate Cancer
M. Craig Miller et al.
JOURNAL OF ONCOLOGY (2010)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen
DS Ma et al.
CLINICAL CANCER RESEARCH (2006)
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer
R Dagher et al.
CLINICAL CANCER RESEARCH (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
